-

Total Voting Rights

DUBLIN--(BUSINESS WIRE)-- 

Mainstay Medical International plc

(“Mainstay” or the “Company”)

Total Voting Rights

In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, Mainstay announces that:

The total number of Ordinary Shares of nominal value €0.001 each in issue on 3 June 2020 is 13,439,004 corresponding to a total of 13,439,004 voting rights. The Company holds no Ordinary Shares in treasury.

Therefore, the figure which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the Transparency (Directive 2004/109/EC) Regulations 2007 and the Transparency Rules is 13,439,004.

Total number of Ordinary Shares outstanding

13,439,004

Total number of theoretical voting rights1

13,439,004

Total number of exercisable voting rights2

13,439,004

3 June 2020

 


1 The total number of theoretical voting rights (or “gross” voting rights) is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
2 The total number of exercisable voting rights (or ”net” voting rights) is calculated without taking into account the shares with suspended voting rights.

Category Code: TVR
Sequence Number: 701112
Time of Receipt (offset from UTC): 20200603T094840+0100

Contacts

Mainstay Medical International plc

Mainstay Medical International plc

Dublin:IRSH

Release Versions

Contacts

Mainstay Medical International plc

More News From Mainstay Medical International plc

Mainstay Medical to Present at the LifeSci Partners Summer Symposium

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that Jason Hannon, Chief Executive Officer, and Matthew Onaitis, Chief Financial Officer, will present a corporate overview at the LifeSci Partners Private Healthcare Company Virtual Summer Symposium on Wednesday, 5 August, 2020. Presentation Details: Date: 5 August, 2020 Time: 2:30 PM ET To register, please click here. About Mainstay Medical Holdings Mainstay Medical Holdings is a medical devic...

Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Premarket Approval (PMA) application for ReActiv8®, its implantable neurostimulation system to treat intractable chronic low back pain. Jason Hannon, CEO of Mainstay, said: “I am so proud of our team and the dedicated physicians who managed our clinical trials and cared for their patients. We are thrilled to receive FDA...

Mainstay Medical Announces Reimbursement Approval for ReActiv8 in Australia

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”), today announced that ReActiv8, its implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, has been approved for inclusion in the Prostheses List of reimbursed products in Australia, effective as of 1 July 2020. The Prostheses List identifies implantable devices eligible for reimbursement from all private health insurance funds in Australia. This approval follows the December...
Back to Newsroom